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 1 
INTRODUCTION 
Vibrio cholerae 
Background 
V. cholerae is a gram-negative bacillus responsible for the severe human diarrheal 
disease cholera, affecting millions annually worldwide (1). V. cholerae naturally reside in 
marine environments including brackish water, and in the environment is often found 
complexed with marine organisms such as plankton or shellfish (2). In human 
populations, infection occurs from the ingestion of contaminated food or water, often 
caused by poor sanitation infrastructure (2, 3). Once inside the host, V. cholerae 
preferentially colonizes the distal small intestine, where it expresses several virulence 
factors in order to establish infection, including the cholera toxin (CT) responsible for the 
watery diarrhea characteristic of cholera, and the toxin-coregulated pilus (TCP) required 
for colonization of the epithelium (4). 
It is uncertain as to when V. cholerae became a human pathogen. Descriptions of 
sicknesses that strongly resemble cholera are described by Hippocrates (~460-377 B.C.E) 
as well as inscriptions found in India dating back to the era of Alexander the Great (356-
323 B.C.E.) (5, 6).The first written documentation of the disease dates to 15th century 
India as European observers began arriving in the country (5). The first global pandemic 
of cholera occurred in 1817, originating from the Ganges river in India (7). This was 
followed by six subsequent cholera pandemics, with the seventh pandemic continuing up 
to the present day (8). V. cholerae was first identified as the etiologic agent of cholera by 
Filippo Pacini in studies of an outbreak in 1854 (9). Of the seven recorded pandemics, the 
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first six were caused by the Classical biotype of V. cholerae, while the ongoing seventh 
pandemic has been due to the newer El Tor biotype originating in South Asia in 1960 (8). 
While like Classical V. cholerae part of the O1 serogroup, El Tor biotype strains are 
characterized by lower toxin production and virulence. As a result El Tor biotype strains 
establish a less severe infection, leading to increased numbers of infected individuals and 
higher asymptomatic carriage (2). Today, infections caused by Classical strains are rarely 
reported.  
The study of cholera has been an important driver of the fields of microbiology 
and our understanding of infectious diseases more broadly. For example, during the third 
pandemic, the efforts of John Snow to trace an outbreak of cholera in London contributed 
to the founding of the field of epidemiology (8).  
 
Symptoms and Treatment 
 The symptoms between Classical and El Tor infections are similar, with El Tor 
typically leading to milder infections (10). Once infected, symptoms can take up to five 
days to develop. The hallmark symptom of this disease is severe watery diarrhea (up to 
18 liters a day). This diarrhea has a distinctive “rice water” appearance caused by the 
presence of numerous Vibrio cells and host mucus (3, 8). Other accompanying symptoms 
include vomiting, muscle cramps and irritability as well as signs of dehydration such as 
loss of skin elasticity, dry mucus membranes, sunken eyes, reduced urine, and in severe 
cases lethargy (11, 12). If left untreated, the infection can cause acidosis, shock, and 
circulatory collapse within hours (8).  
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The principle treatment for a cholera infection is rehydration therapy which drops 
the mortality rate under one percent (8, 12). For severe cases, antibiotics including 
azithromycin and doxycycline for adults and erythromycin or azithromycin for children 
and pregnant women are used in conjunction with oral rehydration (12). Reports also 
indicate that zinc administration can reduce infection duration and severity (10).  
Several vaccines on the market for V. cholerae have been approved by World 
Health Organization (WHO), including Dukoral, Shanchol, Euvichol and Vaxchora (13). 
Dukoral uses heat and formalin inactivated V. cholerae as well as the non-enzymatic B 
subunit of CT and provides a 3-4-year immunity in endemic and industrialized countries 
with approximately fifty percent efficacy. Shanchol also includes heat and formalin 
inactivated V. cholerae as well as the CT B subunit but grants five-year immunity and 
only provides protection to endemic populations with approximately sixty-five percent 
efficacy. Euvichol has similar efficacy to Shanchol except for the vaccine uses only heat 
and formalin inactivated V. cholerae. The most recent commercially available vaccines is 
Vaxchora, a live-attenuated vaccine that provides immunity for at least 6 months using a 
recombinant V. cholerae with a deletion for the genes encoding the CT enzymatic subunit 
and hemolysin A (14). Despite the availability of effective treatment options and some 
prophylactics, the morbidity of cholera is still high affecting up to 4 million annually and 
143,000 deaths, and vaccines have demonstrated highly variable efficacy and typically 
short periods of provided immunity, highlighting the need for preventative care and 
alternative treatments (7). 
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Virulence Factors 
Successful V. cholerae infection of mammalian hosts depends on a carefully 
regulated cascade of gene regulation, culminating in the production of CT, and the 
primarily colonization factor TCP (15, 16). The presence of CT was first proposed by 
Robert Koch in 1884, but it was not until 1959 that it was shown that cell-free culture 
filtrates caused diarrhea (17, 18). This work then led to CT being purified a decade later 
(19). CT consists of a single A subunit and five B subunit that are released by infectious 
V. cholerae cells through a Type II secretion system (18, 19). The two genes encoding 
these subunits, ctxA and ctxB respectively, are carried on the lysogenic vibriophage 
CTXφ. Infection with this phage can render previously non-infectious Vibrio strains 
toxogenic and dangerous (20). Before secretion, five CtxB subunits form a pentamer 
around a single CtxA monomer in the periplasm to form a single holotoxin (21). Once 
outside the cell, each of the monomers of the CtxB can bind with the glycan portion of 
the glycolipid GM1 receptor on epithelial cells lining the intestinal lumen. This 
interaction causes the cell to endocytose the toxin, whereupon the B subunit complex 
creates an opening in the endosome for the A subunit (A1) to enter the endoplasmic 
reticulum. A1 then unfolds, hijacking the cellular machinery allowing for export of 
misfolded proteins into the cytoplasm for proteasomal degradation (22). A1 then folds 
and causes G-protein ADP-ribosylation resulting in the constitutive activation of 
adenylate cyclase, increasing the levels of cAMP. cAMP, in turn, activates a cystic 
fibrosis transmembrane conductance regulator, leading to the constitutive expression of 
the transporter resulting in Cl- leaving the cell. This leads to Na+ loss to maintain 
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electroneutrality, prompting H2O loss and resulting in cholera’s distinctive watery 
diarrhea (23). This diarrhea may then help in elimination of other bacterial competition 
through purging of the gut microbiota and allows for V. cholerae to disseminate into the 
environment later in the infection.  
While CT is required for diarrhea, V. cholerae uses TCP in order promote 
bacterial cell-cell interactions, microcolony formation, and attachment to the host 
epithelium cells, as well as providing receptors for the CTX phage (24, 25). It has been 
shown that the expression of tcpA, the pilin subunit of TCP, is induced an hour after 
inoculation into infant mice, while ctxA, the enzymatic subunit of CT, transcription 
occurred at four hours and that this was dependent on the prior expression of TCP. TCP 
has been shown to be absolutely required for infection of humans and mice (16, 25). TCP 
is a Type IV bundle forming pilus made of many monomers of the pilin TcpA, and the 
genes involved in its biogenesis, encoded in the tcp operon, are transcriptionally co-
regulated with the ctxAB genes encoding CT (25). The TCP biogenesis apparatus can also 
act as a type IV secretion system, leading to the secretion of the soluble virulence factor 
TcpF which has been shown to aid in colonization; ∆tcpF mutants demonstrated a 
decreased colonization in suckling mouse intestines compared to WT (26).  These pili, 
along with exopolysaccharides and proteins, help form a biofilm protecting the cells from 
host immunity, environmental factors and other microbial species (27).  
The initial activation of virulence genes in V. cholerae in vivo is a complex 
process involving several coordinately-expressed regulators and environmental stimuli. 
The cell surface complexes ToxRS and TcpPH can respond to environmental signals, 
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such as oxygen concentration and bile acids to time the expression of downstream 
virulence regulators. ToxRS is able to directly activate CT gene expression, and the 
combined action of ToxRS and TcpPH can stimulate the expression of the master 
virulence regulator ToxT, which can then activate the tcp operon and ctx gene expression 
(28-31). The stability of both ToxRS and TcpPH are tied to bile acids in the host. Bile is 
secreted into the proximal small intestine with a large portion being reabsorbed in the 
distal small intestine where V. cholerae colonizes, and thus serve as an effective 
environmental stimuli of virulence activation in the preferred site of V. cholerae 
colonization (16, 25, 32). ToxS and TcpH are thought to stabilize ToxR and TcpP 
respectively, as mutations of these genes showed an increase in proteolytic activity (30, 
33). It has been reported that proteolysis of ToxR was blocked by the introduction of 
deoxycholate (DC), while TC forms a disulfide bridge to form between two TcpP 
monomers leading to downstream signaling and virulence activation (31, 34). This 
disulfide bridge also serves to protect TcpP from degradation independent of TcpH (35).  
 
Bile Acids 
Synthesis and Regulation 
 Bile acids are molecules in the body derived from cholesterol, synthesized in the 
liver, and stored and secreted by the gall bladder into the small intestine. In the small 
intestines, bile acids play an important role in the emulsification and absorption of dietary 
fats (36). There are two pathways for bile acid synthesis, the classical or neutral pathway 
and the acidic or alternative pathway; together, both pathways utilize seventeen enzymes 
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(32, 36, 37). The classical pathway occurs in the liver and accounts for ninety to ninety-
five percent of all bile acid synthesis (36). Synthesis starts when cholesterol interacts with 
the enzyme CYP7A1, with the end result being either cholic acid (CA) or 
chenodeoxycholic acid (CDCA), which are known as primary bile acids (see Figure 1).  
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Figure 1: Structure and characteristics of bile acids 
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  Figure 1 continued: Structure and characteristics of bile acids 
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The determinative step of bile acid synthesis is the action of enzyme CYP8B1, 
acting as a 12α-hydroxylase by adding a hydroxyl group to C12 of the steroid ring.  If the 
intermediate molecule has the hydroxyl group added, then it will become CA, if not, the 
molecule will become CDCA. The acidic pathway occurs in many different types of 
tissues in the body, with synthesis initiated by one of three enzymes. CYP27A1 is found 
mitochondria of many tissue types, CH25H are found in the endoplasmic reticulum, and 
CYP46A1 is found in the brain (37, 38). It is thought that this pathway is used to control 
lipid homeostasis (38). This pathway produces oxysterol intermediates, which are 
transported to the liver with the end product being CDCA (37). The last step is 
conjugation of the carboxyl group of a bile acid to an amino acid, either glycine or 
taurine in humans, done in a ratio of 3:1 glycine to taurine respectively (36). However, 
diet can affect this ratio; for example, high taurine diets can lead to an increase in taurine 
conjugated bile acids (36, 37) (see figure 2). Bile acid conjugation serves several roles. 
First, since bile acids are hydrophobic, amino acid conjugation makes a portion of the 
molecule hydrophilic, as well as increasing the solubility of the molecule at physiological 
pH (37). Second, conjugation prevents cleavage by pancreatic peptidases that are released 
into the lumen at the same point as bile. Third, conjugation decreases passive 
reabsorption, which allows bile acids to act on food longer. Ultimately, ~95% of the bile 
acids in the gastrointestinal tract is reabsorbed to be reused. Approximately 200-600 mg 
of new bile acids are synthesized by the liver daily, which is roughly equivalent to the 5% 
lost in feces (37). 
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Figure 2: Bile acid biosynthesis. Classical bile biosynthesis is initiated by CYP7A1 
hydroxylation of C7. Alternative biosynthesis is initiated by CYP27A1, CH25H or 
CYP46A1 via hydroxylation of C24, 25, or 27 respectively; an oxysterol intermediate 
that is converted to CDCA when translocated to the liver. CYP8B1 hydroxylates C12 
to the sterol intermediate, the resulting bile acid is CA. Bile Acid: Amino-acid 
Transferase (BAAT) conjugates glycine or taurine to the carboxyl group of 
synthesized bile acids. The resulting conjugated bile acids Glycocholic acid (GCA), 
Taurocholic acid (TCA), Glycochenodeoxycholic acid (GCDCA) and 
Taurochenodeoxycholic (TCDCA) leaves then the hepatocyte. Figure created in 
ChemSketch. Chemical structures based on Structures found on PubChem.com and 
open source material. 
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The concentration of bile acids effect the regulation of their own synthesis. This 
was initially suggested when creation of biliary fistulas resulted in an increase in bile acid 
synthesis. The ability to return bile acid synthesis to a normal level with infusions of bile 
acids into the duodenum was indicative of a negative feedback loop or feedback 
inhibition (39-41). Studies in rats observed increased CYP7A1 activity in animals where 
the luminal bile was reduced by the administration of the bile sequestering 
cholestyramine. The cholestyramine effect was reversed when additional bile acids were 
fed to the animals (37). It has also been shown that CYP7A1 expression can be 
stimulated by cholesterol in rats. Furthermore, bile acids can bind to the nuclear receptor 
FXR and indirectly inhibit CYP7A1 synthesis (37). It has also been shown that glucose 
can increase CPY7A1 gene expression in diabetic patients while insulin inversely 
regulates bile acid synthesis. Diabetic patients saw higher levels of bile acids bile acid 
levels when in a state of hyperglycemia that decreased with insulin treatment (42, 43).  
 
Secretion and Enterohepatic Circulation 
 Once bile acids have been conjugated, they are brought to the gallbladder to be 
concentrated and stored until needed. After a meal, the release of the hormone 
cholecystokinin by the intestinal epithelium causes the gallbladder to release bile into the 
small intestine (44). As bile acids continue down the alimentary canal, they undergo 
chemical changes resulting from interactions with the native microbial flora including 
deconjugation, dehydroxylation and hydroxylation. Deconjugation occurs when the bond 
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between the bile acid and the conjugated amino acid are broken. Dehydroxylation occurs 
when a hydroxyl group is removed from the steroid backbone creating secondary bile 
acids, while hydroxylation involves epimerizing hydroxyl groups from an alpha (α) to a 
beta (β) position or vice versa. (36).  
 Primary bile acids are reabsorbed by the distal ileum as bile acids pass through the 
small intestine, while secondary bile acids are passively absorbed in the large intestine, 
though not as efficiently as primary variants (Table 1). Absorbed bile acids then are 
bound by plasma proteins and shunted back to the liver. Once in the liver, both primary 
and secondary bile acids are conjugated and secreted once again. The exception is LCA, 
which undergoes sulfation at the 3-hydroxyl position (36). This may be to remove LCA 
from the system as sulfated LCA as it is not easily reabsorbed. As a result, the bile acid 
pool is highly diverse (Table 1, Figure 3). 
 
 
Source CA CDCA DCA UDCA LCA Other 
Gallbladder 35% 35% 25% 2% 1% 2% 
Feces 2% 2% 34% 2% 29% 31% 
Table 1: Composition of bile acids in the gallbladder and feces of healthy individuals, 
demonstrating bacterial bile acid metabolism though the gastrointestinal tract. Percentages 
derived from Ridlon et. al. 2006 
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Figure 3: Bile acid metabolism and circulation. In the small intestine bile acids are 
deconjugated by BSH. CA and CDCA metabolized through the 7α-dehydroxylation 
pathway resulting in DCA and LCA respectively.  CDCA is also metabolized by 
7α/β- HDSD enzymes resulting in UDCA. UDCA is metabolized into LCA by the 7β-
dehydroxylation pathway. These bile acids then reabsorbed into the portal circulation 
and transported to the liver or excreted through feces. Black arrow: bile acid 
metabolism, Blue arrow: portal circulation, Red arrow: excretion into feces, Green 
box: BSH deconjugation. Figure created in ChemSketch. Chemical structures based 
on Structures found on PubChem.com and open source material. 
 15 
Function 
Bile acids/salts have many functions in the body.  The most well-known of these 
is solubilizing fats and vitamins, making these molecules available for the body to 
absorb.  This is accomplished by the formation of bile acid micelles with fat soluble 
vitamins, cholesterol, monoglycerides, and fatty acids, acting as a solvent vehicle for 
absorption (32, 36). These micelles are spherical and act in a similar manner as 
phospholipids in cell membranes; the amino acid portion of the bile salt, the hydrophilic 
portion, is exposed to the lumen while the hydrophobic molecules are contained within 
the micelle (36). 
It has also been shown that bile acids act as an antimicrobial agent in the 
alimentary canal. This was first hypothesized after studies showed increased bacterial 
growth with bile duct ligation or in people with cirrhotic livers that had decreased bile 
acid production (45). Further studies have proposed that bile acids accomplish this in 
various ways. Conjugated bile acids, specifically GDCA, decreased the pH of microbial 
cells by causing an influx of protons, forcing cells to put energy into balancing 
intracellular pH (46). Another study suggested that bile acids caused damage to the 
cellular membrane/wall as bacteria exposed to CA and DCA demonstrated signs of 
intracellular leakage through visible changes in cellular morphology, cell survival assays, 
and levels of intracellular material (47). This effect is supported by the fact that bile acids 
possess detergent qualities. It is possible that bile acids can also induce DNA damage as 
Escherichia coli exposed to bile acids activated the promoter for dinD, a gene that is 
induced by DNA damage though the SOS response (48). Bile acids also serve as ligands 
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for nuclear receptors, including FXR. Not only is it involved with the negative feedback 
loop of bile acid synthesis, FXR also plays a role in immunity as a regulator for iNOS 
and IL-18, as well as in other pathways including lipid metabolism, glucose metabolism 
and bile acid transport (49, 50). 
 
Bacterial Effects on Bile Acids 
Bacteria have several methods to modulate and metabolize bile acids and decrease the 
bacteriostatic and bactericidal effects of primary/conjugated bile acids. A major pathway 
for bacterial interaction with bile acids is the action of the enzyme bile salt hydrolase 
(BSH, choloylglycine hydrolase) produced by commensal microbes in the gut and which 
serves to remove the conjugated amino acid on bile acid molecules. Depending on the 
type, this enzyme can be intracellular or extracellular (51). Homologs of this gene can be 
found in many species residing in the small intestine, with each enzyme varying in its 
regulation, subunit size, and function (36). BSH also shows specificity to the different 
conjugated bile acids; Bacteroides thetaiotamicron VPI 5482 is unable to deconjugate 
CA conjugates, but was able to deconjugate CDCA, UDCA, DCA and LCA conjugates at 
different levels (52). The presence and function of these BSH enzymes can vary at the 
strain level within the same bacterial species (see Table 2 and Figure 5 and 6 for 
comparison of bsh in representative bacterial community). Some species host multiple 
bsh genes encoding BSH enzymes; for example Blautia obeum 
 (B. obeum) has two genes, RUMOBE_00028 and RUMOBE_ 03454, that have been 
identified through bioinformatic analyses as encoding BSH (53). In Clostridium 
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perfringens, a strain with its initial bsh deleted (∆bsh) still retained partial deconjugation 
activity, indicating the presence of more than one homolog (54).  
 The most notable microbial dehydroxylation pathway is 7-α/β dehydroxylation, 
which is restricted to deconjugated primary bile acids. This intracellular process utilizes 
several enzymes to convert CA to DCA and CDCA to LCA using 7-α dehydroxylation 
pathway and UDCA to LCA by 7-β dehydroxylation. A well-studied bacterial species 
that metabolizes bile acids in this way is Clostridium scindens, containing a bai operon 
coding for the proteins required for dehydroxylation (36). Dehydroxylation of bile acids 
may serve several purposes in bacteria; it is theorized that bacteria can use bile acids as 
an electron acceptor/carrier (NADP+⇄NADPH, NAD+⇄NADH and ATP→AMP). It is 
also possible that this confers a competitive advantage over other bacteria, since DCA 
and LCA are more inhibitory to sensitive microbes (36). 
 Hydroxylation is a reversable process using two enzymes α and β HSDH 
(hydroxysteroid dehydrogenase). these enzymes act on either the C3, C7 or C12 hydroxyl 
groups on bile acids by oxidation and epimerization. It has been demonstrated that this 
process can occur either within a single species or shared among two (36). The most 
notable are 7-α/β HSDH act on CDCA to make UDCA, a less toxic bile acid as shown in 
a study comparing growth of Clostridium absonum; the bacteria grew on plates with 1 
mM of UDCA but could not grow with the same concentration of CDCA (36, 55). See 
Figure 1 for bile acid properties and Figure 3 for a summarized bile acid metabolism 
pathway. 
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Rodent Models 
Mice are a common animal model used not just microbiome related studies, but in 
studies to understand bile acid synthesis and mechanistic function. It is important to note 
that studies in rodents present a different bile acid pool to microbes than in humans, both 
at the level of synthesis and the relative chemical composition of the final bile acid mix. 
In rats, fasting may stimulate bile acid synthesis as evidenced by the induction of 
CYP7A1 expression (37). The acidic pathway plays a larger role on bile acid synthesis in 
mice than humans.  When comparing CYP7A1 KO mice, their bile acid pool was 25% 
that of WT mice when both were on a normal mouse/rat diet. In CYP7A1 deficient 
humans, however, the bile acid pool is 5-10% that of healthy individuals (56, 57).  People 
with CYP7A1 deficiency experience hyperlipidemic phenotype while CYP7A1 KO mice 
experience normal lipid phenotype (56). On a regular diet of 75 g of fat and 500 mg of 
cholesterol CYP7A1 deficient humans demonstrated more sterols and less fatty acids 
absorption through fecal analysis while CYP7A1 KO mice have been shown to absorb 
<5% of dietary cholesterol (56, 58).  It is important to note that that mouse and human 
diets are quite different, and that diet on its own within either organismal system can 
affect bile acid pools of these organisms. The differences also extend to sex, as female 
mice demonstrate a larger bile acid pool than male, a pattern that is opposite than what is 
seen in humans (59). Mice also can alter a bile acids structure after synthesis by 
rehydroxylating the 7C of secondary bile acids and hydroxylating CDCA into α and β 
muricholic acid (MCA) (36, 60).   
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Rodent-human differences also extend to the composition of the final bile.  In 
addition to having CA and CDCA as major primary bile acids, mice also have MCA, 
with α-MCA and β-MCA being the predominant bile acids (56, 60). MCA is a 6-
hydroxylated bile acid having different forms depending on the steriochemistry of the 
hydroxyl group on C7, with the most common being α and β, the latter being the more 
prevalent of the two (60-62). Murideoxycholic acid (MDCA) and hyodeoxycholic acid 
(HDCA) are also part of the mouse secondary bile acid pool with only trace amounts 
found in humans, where the C7 hydroxyl group has been dehydroxylated (60). Both 
secondary bile acids differ in the C6 hydroxyl group, with one being in the alpha position 
and the other in the beta (60, 63-66). HDCA is formed in two different ways; the first is 
derived from MCA and is strictly microbial where it can go through an additional 
epimerization of the 6C hydroxyl group. LCA can also be metabolized through liver and 
microbial enzymes (67).  Bile acids in the murine bile pool are almost exclusively 
conjugated to taurine (>95%) in contrast to the glycine/taurine conjugated mixture found 
in humans, with sulfation of LCA occurring only in humans (60, 68). Rodent bile acids 
have also been shown to be less hydrophobic than human bile acids (69). 
Despite these differences, mice are useful and an important model for in vivo 
infection and bile manipulation studies. The anatomy and function of the mouse intestinal 
tract is similar to humans, including both digestion and immunity (70). This similarity 
also goes to the genetic level, with humans and mice having 90% of their genes in 
common (71).  Mice can be controlled for genetic variability; inbred mice lines can be 
produced and reduce complications from having a larger gene pool. In addition, mice can 
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be genetically manipulated to knock-in, -out or -down genes of interest. Further, mouse 
diets can be specifically controlled for content and quantity. It is also possible to rear 
mice in germ-free conditions, removing microbial variability and allowing for the 
controlled introduction of specific microbial communities to assay for their effects on the 
host (68). Finally, the generation time is also much shorter with a gestation time around 
21 days and mice reaching maturity between 3-6 months old (72). Mice are specifically 
used for bile acid studies because there are multiple models available such as CYP7A1 
KO lines and humanized liver mouse models (56, 57, 73).  
There are infant and adult models currently used for V. cholerae infection models, 
each with advantages and disadvantages. In suckling animals, V. cholerae colonization is 
dependent on production of TCP and CT, as in humans, however they do not produce the 
large volumes of diarrhea seen in humans (25, 74). The opposite is true for adults, where 
conventional mice are resistant to colonization of V. cholerae. Adult mice only become 
susceptible when they are treated with antibiotics or are reared germ-free, but TCP is not 
needed for V. cholerae colonization (74-76). Thus, adult germfree animals can serve 
largely as a colonization, rather than a virulence, model for V. cholerae. 
 
Effects of Bile Acids on V. cholerae 
Bile has different effects on V. cholerae in the gut. Like other bacteria, bile acids can 
have a toxic effect, requiring V. cholerae to develop defense mechanisms. One of the 
most important defense mechanisms is biofilm formation; in the presence of bile acids 
and crude bile, V. cholerae increases the formation of biofilm through the expression of 
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VpsR (77). However, certain bile acids have shown to be integral in virulence activation. 
This was demonstrated by Yang et. al. who that taurocholate (TC) was able to activate 
virulence gene expression, including TCP and CT production. They were able to show 
that the bile acid acted directly on TcpP, which normally is inactive in a monomer form. 
Under anaerobic/microaerophilic conditions characteristic of the GI tract, TCA acts on 
TcpP by promoting the dimerization via disulfide bridge formation between the C207 
residues of each monomer, resulting in an activated TcpP dimer that activates ToxT 
expression leading to full virulence gene activation (31). A direct effect of bile acids on 
ToxR also had been demonstrated, with ToxR acting on the activation of ctxAB and tcp 
independently of ToxT (28, 34). These differences in responses to bile acids may be 
related to the fact that the strains used in these studies were of the El Tor and the 
Classical biotype respectively. It has also been shown that bile has had the opposite effect 
on virulence expression, more specifically crude ox bile (28, 78). However, oxen are not 
known for being susceptible to cholera infection and they are not used as a cholera 
animal infection model. The complexity of bile acid compositions in the GI tract may 
also contribute to differences in regulation. One study compared three commercially 
available ox gall products, showing conjugated bile acids had different ratios of taurine 
and glycine when compared to human bile and the overall abundance of bile acids were 
CA, DCA, and CDCA respectively compared to CA=CDCA and DCA respectively (36, 
79). It is possible that these ratios have an effect on virulence including a larger 
percentage of a secondary bile acids, which are considered more cytotoxic than primary 
bile acids. It should be noted that there are other components of bile that have been 
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shown to affect virulence expression, specifically, unsaturated fatty acids were shown to 
affect ToxT by affecting the proteins ability to bind to DNA (80). These compounds 
illustrate the complexity of virulence expression for V. cholerae in the small intestine. It 
should also be noted that V. cholerae has a predicted bsh gene (NC_002506.1), however 
its expression, regulation, cellular localization, and substrate specificity have not been 
determined. As of the time of this thesis, we are not aware of any publications that 
address this, and it is unknown as to what affect this has on V. cholerae virulence 
cascade. It is possible that the enzyme may not have an effect on virulence activation if it 
is an intracellular enzyme; the current model for TCA acting on TcpP is an interaction 
occurring in the periplasmic space of the cell (31). If deconjugation occurs intracellularly, 
it is possible that this process is protecting DNA damage and not affecting the pool of 
TCA required for virulence activation. 
 
The Gut Microbiome and Bile Acids 
The microbiome is a complex system within the human GI tract, encompassing 
thousands of different species. This community is not homogenous, and the taxa 
represented can vary dramatically across individuals, ethnicities and human populations, 
though communities are more similar between closely related individuals and within 
closer geographic areas influenced by the food consumed in those areas (7, 42, 81-83). 
Even though these populations differ, it has been shown that the metabolic pathways of 
the community remain similar, highlighting the fact that different bacteria can inhabit the 
same niche/perform similar roles (84).  
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Microbial communities do not remain stagnant and they are ever-changing as a 
result of both internal and external factors. Gastrointestinal infections, such as diarrheal 
diseases, can dramatically but transiently change the composition of the gut microbiome, 
making the microbiome less diverse and abundant, and shifting adult gut microbiomes 
closer in structure to that of infants (85). Diet is another strong driver of the structure and 
abundance of the microbial community in the gut. These changed are seen in 
malnourished individuals, those who consume high fat diets (HFD) and in studies that 
modified ingredients in the diet (86-88). Particularly, HFD have been shown to shift 
phyla in the community to one that has a larger abundance of Firmicutes and less 
Bacteroides (87). Moreover, consumption of high-fat diets in obese participants caused 
an increase in total and secondary bile acids (76). Feeding rats CA caused an increased 
the abundance of Firmicutes and the decrease of Bacteroidetes when compared to the 
control (89). It is possible then that the high fat diet results in an increase in bile acids 
secreted into the small intestine, resulting in increased microbial deconjugation and the 
increase in free bile acids driving the change to a microbiome including a larger 
abundance of firmicutes. 
Hundreds of species contain bsh or putative bsh genes in the gut microbiome. 
These genes vary when comparing sequence homology, and are classified into eight 
phylotypes (36, 90) BSH enzymes from each phylotype were tested for their docking and 
deconjugating ability on primary and secondary conjugated bile acids resulting in 
different deconjugation percentages among phylotypes demonstrating that gut bacteria 
likely have different effects on the bile acid pool (90). As noted above, alteration of the 
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bile acid pool is not restricted to bsh activity, as bacteria can metabolize primary bile 
acids into secondary through dehydroxylation and/or hydroxylation as bile passes through 
the alimentary canal. Therefore, the microbiome is important for shaping the bile acid 
pool and is readily observed by the complex array of bile acids detected in feces (36). 
 
My Research 
My research focuses on the microbiome can downregulate virulence activation in 
V. cholerae, specifically through deconjugation of bile acids. We designed complex 
resistant and dysbiotic microbial communities, using bacterial strains selected to 
represent the human gut microbiome under homeostatic and dysbiotic conditions in 
cholera endemic areas (42, 81, 85, 86, 91, 92). Malnutrition affects the composition of the 
gut microbiome, as seen with children with severe acute malnutrition where the diversity 
of the microbial community was reduced compared to healthy children (91). Diarrheal 
diseases also have been shown to decrease the diversity and increase the proportion of 
streptococcal species, including Streptococcus salivarius (S. salivarius), as well as 
enterococci and enterobacteriaceae (86). Studies following cholera infections found 
bacterial communities during an infection to be similar to malnourished and/or diarrheal 
states, but the communities shifted toward healthy adult-like communities as individuals 
recovered (85). These healthy adult microbiomes the genera Dorea, Bacteroides, 
Collinsella and Blautia are abundant and are correlated or strongly associated with 
disease recovery from a V. cholerae infection, while high levels of streptococcal species 
were associated with diarrhea (85). Moreover, B. obeum was shown to decrease V. 
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cholerae colonization in germ-free mice. Out of the bacteria tested in vitro, B. obeum and 
S. salivarius were identified as species that can and cannot deconjugate TC respectively. 
In studies performed by Salmasadat Alavi, these communities were introduced into 
suckling mice alongside V. cholerae. Salmasadat Alavi also performed studies in germ-
free mice using these communities to look at their effect on V. cholerae colonization. 
Both studies saw B. obeum having a negative effect on V. cholerae colonization, while S. 
salivarius did not. These results coupled with studies with similar associations with these 
bacteria led me to incubate these two species in infant mouse intestinal homogenate, 
showing a decrease in tcp activation compared to control with further testing revealing 
that this effect was not due to AI-2 but by modification to an inducer present in the 
homogenate (79, 80). By testing with cholestyramine and measuring bile acid levels by 
mass spectrometry, we determine that the bile acid TC was involved with tcp induction 
and this signal was being lost due to B. obeium possessing a bsh gene. We looked for bsh 
homologs in the microbial community by in vitro deconjugation of TC and database 
searches. By performing several database searches for bsh homologs in the genomes of 
gut commensals in our representative communities, we identified species that 
deconjugated TC and found two loci in B. obeum as putative encoders of BSH enzymes. 
These findings for Blautia obeum agree with a study looking at the taxonomic profile of 
bsh genes found in BSH-T1 and BSH-T7 phylotypes were seen to be mainly distributed 
in genera including Blautia. BSH-T1 had the highest relative abundance of BSH’s and 
had one of the higher specific activity to bile acids including TC, while BSH-T7 was had 
one of the lowest relative abundance and specific activity (90). One of these genes, 
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RUMOBE_00028, was cloned into a plasmid constitutive expression vector to enable the 
expression of this enzyme in a non-bile acid deconjugating E. coli strain. Using this 
transgenic E. coli, we found in both in vitro and in vivo experiments that B. obeum bsh 
genes were active and able to degrade virulence-gene activating bile acids in mouse 
tissues. We also performed quantitative real-time PCR (qPCR) for RUMOBE_00028 on 
bacterial DNA derived from complete fecal specimens of healthy human donors. When 
comparing to V. cholerae infection experiments, qPCR of the B. obeum bsh enzymes in 
these samples were predictive of the ability of these fecal communities to restrict V. 
cholerae colonization when compared to colonization studies in infected animals.  
Together, these results show that V. cholerae virulence activation is significantly affected 
the structure and BSH activity of human gut microbiomes, which forms a risk factor for 
susceptibility to this important human pathogen. 
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METHODS 
Ethics Statement 
All animal experiments used protocols approved by the Institutional Animal Care 
and Use Committee of the University of California, Riverside (UCR). All human samples 
were part of a study approved by the UCR Institutional Review Board. Both animal and 
human studies followed NIH guidelines. 
 
Animal Experiments 
All CD-1 suckling and adult animals were purchased from Charles River 
Laboratories. 
 
Bacterial Strains and Growth Conditions 
Unless otherwise noted, human gut strains were propagated in LYHBHI liquid 
medium (BHI supplemented to 5g/L yeast extract, 5mg/L hemin, 1mg/mL cellobiose, 
1mg/mL maltose and 0.5mg/mL cysteine-HCl). Cultures were then propagated at 37oC 
either in a Coy anaerobic chamber (5% H2, 20% CO2, balance N2), under microaerophilic 
conditions with Campy BD GasPakTM, or aerobically. All V. cholerae strains were 
derived from the C6706 El Tor pandemic isolate, including the lacZ::PtcpA:sh Ble zeocin 
resistance reporter strain, and propagated in LB media with streptomycin (100μg/ml) at 
37°C. To construct a strain resistant to kanamycin, the plasmid pZE21 was cloned into V. 
cholerae C6706 (C6706-KMR) and propagated in LB with kanamycin sulfate (Fisher 
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Scientific, 50μg/ml) and streptomycin sulfate salt (100μg/ml). Vibrio harveyi BB170 was 
propagated in LM medium aerobically at 37°C. 
To construct a strain constitutively expressing bsh, RUMOBE_00028 was 
amplified from B. obeum genomic DNA using primers 5’-
GTCGACGGTATCGATAATGCTTATGTGTACAGCTGC-3’ and 5’-
GCAGGAATTCGATATCACTAATTCTGAAAATGAATCTGC-3’. This amplicon was 
then cloned downstream of the constitutive PLtet-O1 promoter of plasmid pZE21 through 
digestion of the vector backbone with HindIII followed by Gibson assembly (NEB). The 
resulting plasmid was electroporated into E. coli strain DH5𝛼λpir to generate bshc. 
Strains were propagated aerobically in LB with kanamycin (50μg/ml) at 37°C.  
A strain overexpressing the AI-2 signal of B. obeum (BW30045_RO_AI-2) was 
constructed by electroporating into E. coli BW30045 (ΔluxS) a plasmid constitutively 
expressing the B. obeum luxS AI-2 synthase. The B. obeum luxS coding region (from 
genome Q9KUG4, position 33,305-33,784) was codon-optimized for expression in E. 
coli, placed downstream of the PLtet-O-1 constitutive promoter sequence derived from the 
plasmid vector pZE21 vector, with the construct cloned into vector pMK using the 
GeneArt Subcloning & Express Cloning Service (ThermoFisher). Strains were 
propagated aerobically in LB with kanamycin (50μg/ml) at 37°C. 
 
Human Study Design and Sample Collection  
We collected intact fecal samples from six healthy adult volunteers in University 
of California Riverside using an IRB-approved protocol. Inclusion criteria were: 1) age 
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between 18 and 40 years, 2) must be able to provide signed and dated informed consent, 
3) must be willing and able to provide stool specimen. Exclusion criteria were: 1) 
systemic antibiotic usage (oral, intramuscular, or intravenous) in the 2 weeks prior to 
sampling; 2) acute disease at time of 2 enrollment (presence of moderate or severe illness 
with or without fever); 3) diarrhea (liquid or very loose stools not associated with a 
change in diet) in the 2 weeks prior to sampling; 4) active uncontrolled GI disorders or 
diseases including Inflammatory bowel disease (IBD), ulcerative colitis, Crohn’s disease, 
or indeterminate colitis, persistent, infectious gastroenteritis, colitis, or gastritis, and 
chronic constipation; 5) Major surgery of the GI tract, excluding cholecystectomy and 
appendectomy, but including major bowel resection at any time. Fecal samples were 
collected aseptically from each person at UCR and immediately preserved at −80°C until 
processing for DNA extraction and animal colonization. Stocks of fecal slurries for 
subsequent experiments were prepared by resuspending samples at 1:3 weight/volume in 
sterile reduced PBS and adding sterile glycerol to a final concentration of 25% 
volume/volume. 
 
Preparation of Human Fecal Samples for Inoculation into Mice   
Human fecal slurries were cultured from glycerol stocks in LYHBHI media for 24 
hours at 37°C, and then diluted (1:50) in fresh LYHBHI media. After growth for an 
additional 48 hours, cultures were normalized for density by OD600. For inoculation into 
suckling mice, the equivalent total of 300μl of OD600=0.4 were pelleted by centrifugation 
and resuspended in fresh LYHBHI. Each mouse received this mass of bacterial cells in a 
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maximum gavage volume of 25μl with the remaining 25μl containing ~1x104 CFU V. 
cholerae in PBS. Microbial levels in human fecal slurries were estimated via real-time 
PCR using universal 16S primers as described below, and samples were normalized to so 
that each suckling animal received slurries containing the equivalent of ~20μg of 16S 
amplicon. 
 
Antibiotic Clearance of Murine Microflora in Suckling Mice 
Four-day old suckling CD-1 mice were fasted for 1.5 hours, then orally dosed 
with ~1mg/g body weight streptomycin or using 30-gauge plastic tubing, after which the 
animals were placed with a lactating dam for 1 day. After 24 hours, mice received 
microbial communities with V. cholerae in a maximum gavage volume of 50μl. At 
eighteen hours post-infection, animals were sacrificed, and their intestines homogenized 
for CFU numeration and DNA extraction.  
For mice being pre-colonized with bacteria, four-day old suckling CD-1 mice 
received a ~1/g body weight oral gavage of kanamycin. Infants were colonized 24 hours 
later using overnight cultures of bshC and vector strains grown in LB with kanamycin 
(50μg/ml at 37°C then normalized for density by OD600. For inoculation into suckling 
mice, the equivalent total of 300μl of OD600=0.4 culture was pelleted by centrifugation 
and resuspended in fresh LB with kanamycin (50 μg/ml). 50μl of this was then 
introduced via intra gastric gavage into 5-day old CD-1 suckling mice that had been 
fasted for 1.5 hours. Pups were then returned to a lactating dam. 24 hours after pre-
infection colonization, mice were co-gavaged with 50µl of bshC or the isogenic vector 
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and C6706-KMR. For C6706-KMR, the total resuspension volume of 50μl containing 
~1x104 CFU V. cholerae in LB with kanamycin (50μg/ml); the same CFU of bshC and 
vector strains were gavaged as the previous day. Suckling mice were fasted overnight 
during infection. After eighteen hours post introduction of V. cholerae, animals were 
sacrificed, and their intestines homogenized for CFU numeration. 
 
Purification of Bile Acids from Intestinal Homogenate 
Intestines were collected from six-day-old CD-1 suckling mice fasting for 
eighteen hours, homogenized in sterile H2O (n*2.5ml), pooled, and centrifuged to clear 
tissue debris. The resulting aqueous suspension was treated at 100oC for thirty minutes 
and sterilized with a 0.22µM filter. The resulting sample was desiccated using a Savant 
Integrated Speedvac System (Fisher Scientific) and resuspended in one-fifth volume of 
sterile water. Four volumes of acetonitrile (Sigma Aldrich) were then added and sample 
was vortex and incubated at room temperature for twenty minutes for deproteinization 
(93). Samples were then clarified, with the aqueous layer filter sterilized, desiccated and 
resuspended in one-fifth original volume sterile H2O as described above.  
 
Processing of tcp-Activating Signals by Commensal Bacteria 
Commensal isolate cultures were grown for 2 days then sub-cultured at 3:100 for 
2 days. Growth was measured by OD600 and cultures normalized to 1.5mL of OD600=0.4 
culture. bshc and the corresponding vector strain were grown overnight in LB with 
kanamycin, sub-cultured at 1:100 for 24hr, and normalized as above. Cells were pelleted, 
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the supernatant removed, and cells resuspended in sterile PBS with TC to a final 
concentration of 125uM for in vitro assays; for ex vivo assays cells were resuspended in 
purified homogenate. Cultures grown with antibiotics were washed an additional time 
with 1 volume of PBS prior to addition of TC. Samples were then incubated 
anaerobically for 24 hours at 37oC followed by heat treatment at 100oC for thirty minutes. 
Samples were then cooled to room temperature, centrifuged and the aqueous layer filter 
sterilized with a 0.22μm filter. To sequester bile salts, 12.5mg of cholestyramine resin 
(Sigma-Aldrich) was added to 0.5ml of de-protonated sample, and the mixture incubated 
at 1 hour at 37oC with agitation followed by passage through a 3kDa protein concentrator 
(Pierce PES Protein Concentrators). 
 
Bile-dependent Induction of tcp Gene Expression 
PtcpA-sh Ble was grown as overnight culture, diluted 1:1000 in fresh LB with 
streptomycin (100μg/ml), and grown for ~2 hours at 37°C. Each reaction was prepared in 
40µl of 0.5X LB pH 8.5 medium containing homogenate incubated with bacteria as 
described above or pure solutions of bile salts. TC (Sigma-Aldrich), GC (Sigma Aldrich), 
CA (Alfa Aesar), Taurine (Acros Organics), Glycine (Fisher Scientific), Taurine + CA, 
Glycine + CA, TDC (Sigma-Aldrich), TCDCA (Cayman Chemical), GCDCA 
(FrontierScientific), CDCA (Sigma Aldrich), GDC (Sigma Aldrich) DCA (MB 
Biomedicals), Taurine + DCA, LCA (Sigma Aldrich), UDCA (Alfa Aesar), Tβ-MCA 
(Steraloids Inc.) and β-MCA (Steraloids Inc.) were added to a final concentration of 125 
µM in sterile H2O (for a list of bile acid names, see Figure 1).  
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2µl of reporter strain subculture was then added, and samples incubated 
anaerobically at 37°C for four hours. 2µl of each reaction was then added to 200µl of 
0.5X LB pH 8.5 +/-10µg/ml of zeocin (Sigma Aldrich), incubated for thirty minutes 
aerobically at 37°C with agitation. Samples were then serially diluted and plated onto 
streptomycin (200μg/ml) LB agar plates to determine survival rates, defined as (zeocin-
treated sample CFU/average CFU of no zeocin control) *100. 
 
Autoinducer-2 Heat Stability Assay 
Cultures of BW30045_RO_AI-2, BB170 and C6706 were grown overnight. 
BW30045_RO_AI-2 was sub-cultured at 1:100 into 12ml of LB and grown in a shaker at 
37oC until OD600 ≈ 0.22, centrifuged, and the supernatant filter sterilized. For heat 
treatment, aliquots of supernatant were treated at 100oC for thirty minutes and cooled to 
room temperature. AI-2 activity was assessed using the BB170 bioassay (94). Briefly, 
overnight cultures of reporter strain BB170 in LM medium was diluted at 1:1000 into AB 
medium. 10μl of supernatant or heat-treated supernatant were then added to 90µl of 
BB170 dilution. Luminescence and OD600 of each sample were measured immediately, 
and at 3.5hrs, with growth at 30oC aerobically with agitation. 
 
Identification of Bile Salt Hydrolase Homologs 
Using the Kyoto Encyclopedia of Genes and Genomes (KEGG), the Universal 
Protein resource (UniProt) and the National Center of Biotechnology Information (NCBI) 
protein database, we were able to identify bsh homologs and compared amino acid 
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sequences between species using NCBI blastn and blastp respectively. Percent identity 
matrices were constructed using results of pairwise comparison between species using 
Clustal Omega and MUSCLE provided through European Molecular Biology Laboratory.  
 
Quantification of Bile acids with Mass Spectrometry  
All standards (TC, CA, and DCA) were submitted as 10mM solutions. LC-MS 
analysis of bile acids was performed on a Synapt G2-Si quadrupole time-of-flight mass 
spectrometer (Waters) coupled to an I-class UPLC system (Waters). Separations were 
carried out on a CSH phenyl-hexyl column (2.1 x 100 mm, 1.7 µM) (Waters). The mobile 
phases were (A) water with 0.1% formic acid and (B) acetonitrile with 0.1% formic acid. 
The flow rate was 250 µL/min and the column were held at 40° C. The gradient was as 
follows: 0 min, 1% B; 1 min, 1% B; 8 min, 40% B; 13 min, 58.8% B; 13.5 min, 100% B; 
15.5 min, 100% B; 16 min, 1% B; 18 min, 1% B. Flow rate was ramped to 600 µL/min at 
13.5 min to speed up column flushing and re-equilibration. The MS was operated in 
positive ion mode (50 to 1200 m/z) with a 100 ms scan time. Source and desolvation 
temperatures were 150° C and 600° C, respectively. Desolvation gas was set to 1100 L/hr 
and cone gas to 150 L/hr. All gases were nitrogen except the collision gas, which was 
argon. Capillary voltage was 1 kV. Injection volume was 1μl for all samples. The identity 
of bile acids in samples was confirmed by mass, retention time, and MS/MS as compared 
to authentic standards. Samples were analyzed in random order and injected in duplicate. 
Leucine enkephalin was infused and used for mass correction. Data processing (peak 
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integration) was performed using QuanLynx software (Waters). Accuracy of peak 
integrations was checked manually. 
 
In vitro Processing of Bile by Human Complex Fecal Communities 
The ability of a complex human donor fecal community to process taurocholate 
was assayed in vitro. 100μl of fecal slurries in glycerol prepared were inoculated into 5ml 
LYBHI and incubated anaerobically for 2 days at 37°C. Cells were then pelleted, 
normalized to ~OD600 =0.4 in 1.5ml sterile PBS with 125μM TC and incubated 
anaerobically at 37°C for 24hrs with a TC control. Supernatants were then collected via 
centrifugation and heat treated at 100oC for thirty minutes then sterilized with a 0.22μm 
filter then submitted for Liquid Chromatography Mass Spectrometry. 
 
Quantitative Real-Time PCR 
Levels of the B. obeum bsh enzyme (RUMOBE_00028) were determined by real-time 
PCR. Reactions comprised 2 μl of extracted DNA as template, 12.5 μl SYBR Green 
Master Mix (BioRad), 10 μl PCR-grade water, and 0.25 μl of forward and reverse 
primers at 10μM (5’-GCGATCAGATTACGATCACTC-3’ and 5’-
GCCATGCCAACACCTTTTTC-3’). 200ng of purified DNA from intestinal 
homogenates of CD-1 mice colonized with complex human fecal samples were used as 
template for each reaction. Cycle conditions were 95°C for 3 min, followed by 39 cycles 
(95°C for 10sec, 55°C for 30 sec, 95°C for 10 sec, 65°C for 5 sec, 95°C for 5 sec).  
Average Cq results were used to compare to in vivo V. cholerae colony counts.  
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Total bacterial load in fecal samples were determined by quantitative real-time 
PCR as described above, using the primers forward: 5’-CTCCTACGGGAGGCAGCAG-
3’ and reverse: 5’-TTACCGCGGCTGCTGGCAC-3’. 
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RESULTS 
Complex Resistant Microbiomes Suppresses V. cholerae Colonization 
How the microbiome affects V. cholerae colonization in the gut is the central 
question of this thesis. Studies show that pressures such as diarrhea and malnutrition 
decrease the diversity of the gut microbiome and increase the abundance of specific 
species including Streptococci, enterococci and enterobacteria, creating a dysbiotic 
microbiome (42, 79, 80, 91-93). Healthy microbiomes have also been profiled, and 
increases in Dorea, Bacteroides, Collinsella and Blautia, which are characteristic of 
healthy individuals, have been associated with recovery from cholera and malnutrition 
(85, 91). Based on these studies, we designed a complex resistant (CR) and a dysbiotic 
(DS) microbiome. The CR community encompassed thirteen diverse species based on 
16S rRNA that are commonly associated with healthy adult-associated microbiomes. The 
DS contained five species based on diarrhea-associated microbiomes and represented less 
taxonomic diversity (see Table 2). In studies performed by Salmasadat Alavi in the Hsiao 
laboratory, these communities were introduced into antibiotic cleared suckling mice by 
gastric gavage alongside V. cholerae infection, with their intestines collected and 
homogenized eighteen hours post-infection. Results showed that the presence of CR 
communities statistically significantly and dramatically lowered V. cholerae colonization 
compared to DS communities. In addition, co-administration of DS and CR microbiomes 
(or just a subset of the CR community) showed a rescue of the CR colonization resistance 
phenotype (data not shown), suggesting that the metabolic or enzymatic activity of CR 
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and SR microbes are able to compensate or suppress the activity of DS microbes as they 
pertain to affecting V. cholerae infection. 
Another study from Salmasadat Alavi involved collecting fecal samples from 
healthy individuals that were prepared and stored in -80oC in 25% volume/volume 
glycerol. These slurries were cultured and introduced into antibiotic cleared suckling 
mice by gastric gavage with V. cholerae, with their intestines collected and homogenized 
eighteen hours post-infection. Results demonstrated each community had different effects 
on V. cholerae colonization with the CR community being having the greatest effect on 
ablating pathogen colonization (data not shown), emphasizing the complex and 
individual-specific interaction between pathogen and the host microbiome. 
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Bacterium Community Strain Name 
NCBI 
Taxonomy 
ID 
Bacteroides caccae CR ATCC 43185 411901 
Bacteroides thetaiotamicron CR VPI-5482 226186 
Bacteroides uniformis CR ATCC 8492 411479 
Bacteroides vulgatus SR, CR ATCC 8482 435590 
Bifidobacterium longum subsp. 
Longum CR DSM 20219 565042 
Blautia obeum SR, CR ATCC 29174 411459 
Blautia torques CR ATCC 27756 411460 
Clostridium scindens SR, CR ATCC 35704 411468 
Collinsella aerofaciens CR ATCC 25986 411903 
Dorea formicigenerans CR ATCC 27755 411461 
Dorea longicatena CR DSM 13814 411462 
Eubacterium rectale CR ATCC 33656 515619 
Faecalibacterium prausnitzii CR DSM 17677 411483 
Enterococcus faecalis DS OG1RF 474186 
Escherichia coli DS DH5α 668369 
Streptococcus infantarius subsp. 
infantarius DS 
ATCC BAA-
102 471872 
Streptococcus salivarius subsp. 
salivarius DS ATCC 13419 1304 
Streptococcus salivarius subsp. 
thermophilus DS DSM 20617 1091038 
Table 2: Human gut commensal strains, SR= Simple resistant, CR= complex resistant, 
DS= dysbiotic 
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An ex vivo Model of tcp Induction  
 V. cholerae in vivo virulence expression, and thus colonization, is regulated by 
numerous environmental cues, which can be mimicked in vitro using specific culture 
conditions such as microaerophilic/anaerobic growth with the addition of bile acids such 
as TC (28-31, 33, 34). To determine the relative contribution of bile acids and other in 
vivo compounds in virulence activation, the intestines of suckling mouse were processed 
via homogenization, heat treatment and deproteinization and assayed for their ability to 
activate a tcp transcriptional reporter. This reporter strain contained a PtcpA –sh ble 
construct inserted into the lacZ locus of V. cholerae C6706; activation of tcp genes in this 
strain confers resistance to the bactericidal antibiotic zeocin. Due to the age of the infants 
and the amount of material required, samples were concentrated before downstream 
processing. To determine the effect homogenate had on tcp induction, PtcpA –sh ble was 
incubated anaerobically for four hours with purified intestinal homogenate from suckling 
mice, and then subjected to zeocin for thirty minutes. Surviving V. cholerae were then 
enumerated by serial dilution and plating on LB agar with streptomycin. As has been 
reported previously(31), a major component of the virulence-inducing activity of 
intestinal homogenates was due to bile acids; intestinal homogenates demonstrated tcp 
induction levels similar to that of pure 125µM TC solution (Figure 4A).   
 To determine bacterial effects on induction, purified intestinal homogenate was 
incubated with either B. obeum, S. salivarius or a mixture of the two; B. obeum was 
selected due the strong association the bacteria has to V. cholerae recovery and 
decreasing colonization in germ-free mice (79), while S. salivarius has been shown to 
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increase in diarrheal diseases, making these two strains a subset of the CR and DS 
communities (79, 80). The bacteria were grown anaerobically for two days then pelleted 
and resuspended in purified homogenate to a concentration ~0.4 OD600 for twenty-four 
hours. Samples were then heat treated for 30 minutes at 100oC, sterilized using a 0.22 µM 
filter and used for a tcp induction assay. Compared to S. salivarius, B. obeum was able to 
significantly lower induction of homogenate compared to the TC control and S.  
salivarius alone (Figure 4B). These results suggest that B. obeum is affecting levels of 
this activating signal in intestinal homogenates (31). 
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Figure 4: tcpA-activating signals in TC solution and suckling CD-1 mouse 
homogenate (A) and modulation of tcpA-activating signals in homogenate by pure 
cultures of B. obeum and S. salivarius (B). PtcpA-sh ble induction results were 
normalized to PBS with 125µM TC control. Error bars calculated using ±SEM based 
on unpaired t-test. ***P-value< 0.001 
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B. obeum Effects on Intestinal Homogenate Activation of tcp is not due 
to AI-2 Activity 
 B. obeum has also been shown to suppress V. cholerae virulence expression 
through the production of AI-2 quorum sensing signals (79). To determine if these signals 
were solely responsible for the suppression of PtcpA –sh ble induction by intestinal 
homogenates and TC, we examined the ability of heat treatment to differentially affect 
virulence-regulatory signals. Bile acids have previously been demonstrated to be heat-
resistant; heat treatment did not affect the ability of TC to interact with TcpP (31). To 
determine if AI-2 molecules made by B. obeum were heat labile, supernatants were 
collected from stationary cultures of V. cholerae and BW3114_RO_AI-2, which is an E. 
coli strain mutated for luxS, the AI-2 synthase, and which instead constitutively expresses 
the AI-2 synthase enzyme of B. obeum. Supernatants were collected, heat treated for 
thirty minutes at 100oC and sterilized using a 0.22 µM filter. To assay for AI-2 activity, 
we used the Vibrio harveyi strain BB170, which contains an intact lux operon responsible 
for bioluminescence in the presence of AI-2. When BB170 was grown in the presence of 
heat-treated supernatants, heat-treated samples induced very little luminescence in 
comparison to non-heat-treated supernatants (Figure 5). These results indicate that 
treating samples with heat is enough to remove any AI-2 signal from solution and that 
virulent expression is affected by other means.  
 
 44 
 
 
 
Figure 5: Induction of BB170 AI-2 reporter by B. obeum (A) and C6706 (B) with and 
without heat treatment. Induction measured by luminescence/OD600. Error bars 
calculated using SEM Significance based on unpaired t-test. ****P-value< 0.0001 
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Bile Sequestration Does Not Affect B. obeum’s Effect on V. cholerae 
Virulence Activation  
 Previous work indicates that a key activating signal in intestinal homogenates are 
bile acids (31). To confirm if bile acids, which are highly heat stable, were causing V. 
cholerae virulence expression, infant mouse intestinal homogenate was once again 
treated with B. obeum and S. salivarius with the addition of cholestyramine (31). A 
solution with 125 µM of taurocholate TC was used as a positive control. Cholestyramine 
is a resin that binds to bile acids resulting in sequestering the steroid derivative and 
preventing interaction with the environment. It is used as a medication to treat 
hyperlipidemia; with the increased loss of bile acids through feces the liver increases bile 
acid synthesis and resulting in reduced cholesterol levels (37, 39). Pure TCA and mouse 
intestinal homogenates without bacterial treatment strongly induced tcp transcription. 
Again, incubation of homogenates with B. obeum ablated tcp induction and S. salivarius 
had no effect on homogenates’ ability to induce virulence genes. Bile sequestration 
largely eliminated the ability of intestinal homogenates to activate tcp, confirming the 
role of bile acids in virulence induction in this system. Significantly, S. salivarius treated 
homogenates incubated with cholestyramine were largely unable to induce virulence, 
suggesting that the ability of these organisms to affect bile acid levels is a key driver in 
virulence activation by host intestinal signals. There was also no difference observed in 
virulence inducing capability of B. obeum treated homogenates incubated with and 
without cholestyramine (Figure 6A). These sample were analyzed by LC-MS to 
determine the level of dehydroxylation bile acids in the homogenate by the UCR 
 46 
metabolomics core, using pure solutions of TC and CA as standards. Measuring peak 
area, the relative abundance of B. obeum and B. obeum + S. salivarius treated 
homogenate had significantly lower levels of TC compared to S. salivarius and untreated 
homogenate. Interestingly, the opposite was true for CA (data not shown). These results 
indicate that V. cholerae tcp expression is dependent on the bile acids in the mouse 
homogenate and these signals are being affected by B. obeum though BSH activity 
(Figure 6B).  
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Figure 6: Modulation of tcpA-activating signals in suckling CD-1 mouse 
homogenates by pure cultures of B. obeum and S. salivarius as seen by PtcpA-sh ble 
induction (A) and peak area of TC by LC-MS (B). PtcpA-sh ble induction results were 
normalized to PBS with 125µM TC control Note TC Sample was not treated with 
cholestyramine. Peak area describes the relative abundance of bile acid per group. 
Error bars calculated using ±SEM based on unpaired t-test. *P-value< 0.05, **P-
value<0.01, ****P-value<0.0001 
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bsh In the Model Microbiomes 
 The remainder of the bacterial strains in our model communities were 
investigated for their ability to affect TC induced virulence gene expression by incubating 
125 µM of TC with pure cultures of these species for twenty-four hours then were heat 
treated and filter sterilized, and measuring how the resulting cell-free supernatants were 
able to induce a tcp expression in PtcpA-sh-ble. Dramatic differences in the ability these 
strains to affect TC induction of virulence as measured by survival after zeocin treatment 
were observed, with members of the CR microbiome in general being better able to 
prevent tcp activation. This varied at the genus level, with Blautia torques unable to 
affect tcp induction by TC in comparison to B. obeum, and Streptococcus infantarius 
showing TC effects in comparison to the rest of the Streptococcus species in the DS 
community (Figure 7). Levels of tcp induction were higher in groups including E. 
faecalis and S. salivarius. Although currently unknown, it is possible that these species 
boost virulence induction by some mechanism. 
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Figure 7: Ability of CR and DS-member pure cultures to interfere with TC activation 
of PtcpA in V. cholerae in vitro. PtcpA-sh ble induction results were normalized to 
PBS with 125µM TC control Error bars calculated using ±SEM based on unpaired t-
test. *P-value< 0.05, **P-value< 0.01, ****P-value< 0.0001. 
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To search for bsh homologs in our community we searched the KEGG, UniProt 
and the NCBI protein databases using the EC designation 3.5.1.24 and bacterial species. 
Homologs were identified within the CR and DS microbial communities, with putative 
bsh genes in thirteen of the species of which six had multiple copies. B. obeum genes 
CK5_10630 and CK5_18830 were identified from the genome of the strain A2-162. 
When compared to homologs in the B. obeum ATCC 29174 used in our described 
experiments, there are mild difference in amino acid sequences with percent identity 
ranging between 80-90%, showing a higher similarity compared to other genes in the 
community (Table 3 and Figure 8). There were bacteria in the communities that 
demonstrated no effect on V. cholerae tcp expression, such as Bacteroides 
thetaiotamicron, have bsh homologs based on our database search. This is in congruence 
with previous metagenomic analysis of amino acid similarity to a reference BSH ranging 
from 25-100% identity, as well as reports in bsh differences in amino acid sequence and 
preference in bile acid deconjugation leading to the assignment of genes into eight 
phylotypes (52, 53, 86). Together, these results suggest that there are bacteria in our 
microbial community have bsh that may affect other conjugated bile acids rather than TC. 
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A Putative B. obeum bsh Ablates tcp Activation by TC and Intestinal 
Homogenates  
 Based on our findings, we wanted to determine if the bsh gene alone was enough 
to negatively affect V. cholerae tcp activation. We constitutively expressed, 
RUMOBE_00028 from B. obeum to be cloned and expressed in E. coli DH5αλpir, which 
does not process TCA (53). The gene from B. obeum was amplified from purified 
genomic DNA by PCR and cloned downstream of a constitutive PLtet-O-1 promoter on 
plasmid pZE21 in E. coli DH5αλpir to generate strain bshC. The DH5αλpir with an empty 
vector did not degrade TC in infant homogenate as measured by Liquid chromatography 
mass spectrometry and in vitro PtcpA-sh-ble induction (see Figure 9A and 9B). 
Incubation of homogenate with bshC significantly ablated the tcp incubation of 
homogenate duction compared to the isogenic vector control (see Figure 11B), suggesting 
RUMOBE_00028 alone can alter V. cholerae virulence activation though deconjugation 
of TC. 
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Figure 9: Modulation of tcpA-activating signals in suckling CD-1 mouse 
homogenates by pure cultures of bshC, vector and S. salivarius as seen by peak area of 
TC by LC-MS (A) and in vitro PtcpA-sh ble induction (B). PtcpA-sh ble induction 
results were normalized to PBS with 125µM TC control. Peak area describes the 
relative abundance of bile acid per group. Error bars calculated using SEM 
Significance based on unpaired t-test. *P-value< 0.05, **P-value<0.01, ****P-
value<0.0001 
 55 
RUMOBE_00028 Alone is Sufficient to Reduce V. cholerae Colonization  
 To determine if RUMOBE_00028 was sufficient to affect V. cholerae 
colonization, five-day old kanamycin treated infant mice were colonized with bshC or the 
vector strain by gastric gavage. After twenty-four hours, these mice were gavaged with a 
co-culture of either bshC or the vector strain with and C6706 containing a kanamycin 
resistant plasmid by gastric gavage and left fasting. Eighteen hours after, small intestines 
were removed and homogenized. V. cholerae was enumerated by serial dilution and 
plating on streptomycin LB agar. There was a significant decrease in V. cholerae levels in 
bshC colonized animals, indicating that deconjugation by RUMOBE_00028 alone can 
decrease V. cholerae colonization (see Figure 10). 
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Figure 10: Effects on V. cholerae infection of suckling CD-1 
mice by 1-day pre-colonization with indicated E. coli strains. 
Error bars calculated using ±SEM based on unpaired t-
test.***P-value< 0.001 
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Interpersonal Differences in B. obeum bsh Levels in Complex Human 
Fecal Microbiomes Explain Differences in Resistance to V. cholerae 
Infection 
 Since Blautia demonstrated intra-genus differences in BSH activity, as well as 
association with cholera in human populations, we assayed for the level of the B. obeum 
bsh gene by real-time PCR in total DNA extracted from human fecal samples provided 
by healthy donors that did not have: (a) an acute disease or uncontrolled GI disorders or 
diseases, (b) any antibiotic usage or diarrhea two weeks prior to sample collection and (c) 
did not have major surgery of the GI tract (79). We found that communities associated 
with higher V. cholerae colonization had lower levels of RUMOBE_00028 (Figure 12). 
These results mimic the bile acid levels seen in Figure 11, again highlighting the trend 
among V. cholerae CFU of mice colonized with donor bacteria.  
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Figure 11: Result of incubation of TC solution with cultured samples of human fecal 
communities, †: TC not detected in sample. Peak area describes the relative 
abundance of bile acid per group. 
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Figure 12: (A) Real-time PCR quantification of B. obeum bsh in DNA extracted from 
mice colonized with indicated complex human fecal samples. (B) shows resulting V. 
cholerae CFU (mean log per group) after infection of animals containing indicated 
complex human fecal sample. V. cholerae CFU provided by Salmasadat Alavi. Error 
bars calculated using ±SEM. 
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To determine whether these findings corresponded to functional degradation of TC, 
bacterial colonies were grown from donor fecal samples and then incubated in vitro as 
described above followed by heat treatment, filter sterilization and submitted for LC-MS. 
Levels of TC tended to be elevated in groups with increased V. cholerae counts when 
tested in vivo. DC was also found in each group, indicating that there were species that 
contained an intact 7α-dehydroxylation pathway. This is expected as 16S revealed 
bacteria that belong to Clostridium cluster XIVa were present and most 7-
dehydroxylation bacteria are come from this culture (95) (data not shown).  
 
Variation in Bile Acids Effect on V. cholerae Virulence 
Previous studies that looked at bile acids activating V. cholerae virulence 
expression looked at a subset of total bile acids found in bile (31, 33). Therefore, we 
again tested tcp induction using our reporter assay and screened a panel including 
primary bile acids, individual amino acids, conjugated forms, secondary bile acids and 
several murine derived forms. When tested, amino acid alone or adding taurine or glycine 
to deconjugated bile acids was not enough for tcp induction, highlighting the need for 
conjugation (see Figure 15A). Except for TCDCA, we saw human primary conjugates 
induce higher virulence gene expression in V. cholerae compared to secondary 
conjugates and unconjugated bile acids. This highlights the need for conjugated bile acids 
for V. cholerae to properly express tcp. Interestingly, GCDCA had the highest induction 
when compared to other bile acids (see Figure 15B). It is important to note that glycine 
conjugates resulted in higher percent survival compared to taurine and that murine 
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derived bile acids showed low induction. It is possible that this is due to humans having a 
3:1 ratio of glycine to taurine conjugates with the disease evolving to be a human 
pathogen, utilizing bile acids found in this environment (37).  
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Figure 13: Ability of indicated bile acid species(B) and amino acids (B) to activate 
tcp gene expression in V. cholerae. PtcpA-sh ble induction results were normalized to 
PBS with 125µM TC control. Error bars calculated using ±SEM based on unpaired t-
test. 
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DISCUSSION 
 The mammalian small intestine is a complex cellular and molecular milieu that 
enteropathogens must navigate to protect themselves from bactericidal and bacteriostatic 
effects of host components and the activity of commensal microbes. However, some of 
the molecules in this environment also act as signals that provide important timing cues 
for virulence gene regulation. The ability of pathogens to sense these signals ensures that 
metabolically expensive virulence regulons are only expressed in suitable environments. 
For example, in V. cholerae, utilization of bile acids and microaerophilic/anaerobic 
conditions to induce CT and TCP activation (28, 31, 34). Important signals like bile acids 
however are chemically diverse and variable in composition between individuals in part 
due to the ability of native gut microbial communities to process bile acids. 
 Through in vitro and ex vivo screening, mass spectrometry, and genomic analysis, 
we were able to identify gut community members that deconjugate TC through bsh 
activity. This screen also revealed gut strains that contain putative bsh genes but do not 
deconjugate TC, supporting studies have shown bsh variation in both sequence and 
function, with bsh enzymes being broadly grouped into 8 phylotypes by amino acid 
sequence identity and biochemical activity against specific bile species (51, 53). 
Therefore, different communities may exhibit varying levels of cumulative bsh activity. It 
is still unclear how differences in community bsh function, specificity, and activity 
translates into the final bile pool composition of the gut. However, it is reasonable to 
hypothesize that a host’s microbiome diversity and abundance of these enzyme 
phylotypes decreases or disappear completely, as seen in microbial communities with 
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patients experiencing diarrhea or antibiotic treatment, would lead to changes in the 
deconjugated bile acid profile. Humans with dysbiotic gut microbiota have been shown to 
have a decrease in bacterial diversity, and therefore I propose there would be correlated 
decreases in bsh homologs (84, 85, 97). 
 One study that indirectly supports this proposition examined patients infected 
with Clostridium difficile and profiled the microbiome and bile acid pools before and 
after fecal transplant therapy. Prior to treatment, individuals had decreased diversity in 
their gut microbiome, higher conjugated bile acids, and lower levels of secondary bile 
acids. After the patient gut microbiomes were restored via fecal transplants, microbial 
and bile acid pool diversity increased (97). In germ-free mice that lack all of their gut 
microbes exhibit a similar pattern and have been shown to have bile acid pools that are 
predominated by conjugated bile acids and secondary bile acids are virtually absent with 
the exception of taurine conjugated UDCA (98).  
 Given that bile acids are important virulence signals for V. cholerae and that 
resident microbes can alter the composition of bile acids present, we examined how 
microbial communities of different composition might affect V. cholerae colonization. Of 
the bile acids tested on V. cholerae, our results saw primary conjugated bile acids having 
the greatest effect on the expression of tcp. These results suggest that communities with a 
higher abundance of bsh genes or 7-dehydroxylation pathways would create an 
environment unfavorable for V. cholerae colonization by a repression of virulence 
activation. Conversely, we expect that communities with lower abundance of the genes 
involved in these pathways to great a more favorable environment for V. cholerae 
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colonization. We propose that dysbiotic gut communities, like those found in 
malnourished or having recently experienced diarrhea would be favorable for 
colonization because these patients generally have significantly lower bacterial diversity 
and are likely to in turn have lower diversity of bsh genes or 7-dehydroxylation 
pathways. This could result in conjugated primary bile acids encompassing a larger 
percentage of the total bile acid pool and secondary forms decreasing in abundance. 
 Through studies performed by Salmasadat Alavi and studies in this thesis, B. 
obeum and, specifically, the bsh gene RUMOBE_00028 are shown to have a detrimental 
effect on V. cholerae virulence activation and colonization. This enzyme efficiently 
deconjugates TC and converts TC into CA. S. salivarius lacked significant bsh activity 
under our conditions and had a no or a slightly positive effect on V. cholerae virulence 
activation (Figure 4, 6, 7). I also identified additional bacterial strains that had significant 
effects on tcp activation (B. uniformis, B, vulgatus, B. longum, D. longicatena and E. 
rectale) and the regulation and activity of these enzymes will be the subject of further 
research in the lab. Curiously, S. infantarius from our DS model community encodes an 
intact bsh gene and demonstrated deconjugation of TC in vitro. However, the presence of 
this microbe did not act to inhibit V. cholerae infection in vivo as we might expect. One 
possible reason is that the expression or activity level in vivo of this enzyme is absent or 
down regulated. Another possible explanation is that different species establish 
differently in the small intestines causing bsh to be more abundant in different 
sections.Very little work has addressed the possibility of bsh regulation, and it is possible 
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that bile concentration is not the only determinant in bsh expression, nor may every bile 
acid be equal in terms of regulating bsh.   
 It is important to note that, while examining the genomes of our defined model 
communities, a functional search revealed that V. cholerae contains a bsh gene (Locus: 
VCA0877). To our knowledge, no studies are available that describe the ability of this 
predicted V. cholerae enzyme to process bile acids. Homologs of bsh have also been 
found in other pathogenic bacteria, specifically Listeria monocytogenes and Brucella 
abortus, and a search in UniProt found homologs in Salmonella enterica and Yersinia 
enterocolitica (101). Given the necessity of gut-resident organisms to deal with the anti-
microbial effects of bile, the ability of pathogens to process bile into less toxic forms is 
not surprising. What is not known is how these enzymes, and specifically the enzyme in 
V. cholerae is able to work on particular components of the bile acid pool; V. cholerae 
BSH was closest to the BSH type 6 (BSH-T6) phylotype as defined by Song et al. (Table 
4). BSH-T6 enzymes have demonstrated no deconjugation capabilities to GCA or TCA, 
bile the acids we have shown to be strong activators of tcp, while deconjugating 
secondary bile acids that have bacteriostatic function instead (89). It is reasonable to 
hypothesize that this is a beneficial adaptation by deconjugating potential inhibitors of 
growth while sparing those bile acids that are used for tcp activation. B. obeum’s BSH 
was closest to the BSH-T1 phylotype. This is in line with Song et al. with BSH-T1 
phylotype demonstrating almost 100% deconjugation of TCA and the fact B. obeum 
demonstrated one of the highest BSH activity against TC in our community (89).  
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BSH phylogenetic 
Group 
V. cholerae 
Percent Identity 
B. obeum 
Percent 
Identity 
BSH-T0 25.42 26.78% 
BSH-T1 22.63% 76.31% 
BSH-T2 21.94% 59.69% 
BSH-T3 22.58% 47.38% 
BSH-T4 22.74% 39.18% 
BSH-T5 24.72% 28.08% 
BSH-T6 45.53% 23.05% 
BSH-T7 22.58% 24.18% 
 
 
 
 
  
  
  
Table 4: Comparison of V. cholerae and B. obeum BSH 
amino acid sequence against a reference BSH enzyme from 
each phylotype as described by Song et al. Highlighted 
percent identity indicate closest similarity to phylotype. 
Percent identity determined by NCBI BLASTp. 
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 Future work will focus on the other microbial species in the communities. The 
establishment of phylotypes of the bsh has led to a broad classification of deconjugation 
ability in these genes. More species found within these bsh types should be tested to 
determine if the enzymes effect on conjugated bile acids are the same; additionally, these 
phylotypes should be tested against all conjugated bile acid types found in humans to get 
a better understanding as to why bsh has specificity, and how the expression of these 
enzymes are regulated. Studies to look into bsh gene regulation would include incubation 
with different concentrations and types of bile acids, coupled with qRT-PCR to determine 
if bile acids are acting directly on bsh expression. It is also important to note that 
deconjugation can be an intracellular or extracellular process (51). This can be tested by 
comparing cytoplasmic, membrane, and extracellular fractions of bacteria with a 
functional bsh. Other studies to be performed on complex communities’ effect on V. 
cholerae colonization through bsh intervention focusing on having bacteria with bsh 
genes from all eight phylotypes and their effect on the bile acid pool as well as profiling 
the genes expressed in these communities. Additional studies will focus on microbial 
7α/β-dehydroxylation should be studied. This process creates the secondary bile acids 
seen in the human gut and our results demonstrate that secondary bile acids demonstrated 
lower tcp expression than primary, possibly leading to an additive effect on V. cholerae 
colonization over and above the degradation of virulence inducing bile acid species (36).  
 In addition, we will examine the role of bsh in providing protection from bile 
acids (46). By creating ∆bsh mutants in V. cholerae, the effects bile acids have on these 
bacteria can be tested in in vitro and in vivo assays. Also, a more comprehensive 
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examination on conjugated bile acids should be performed on tcp expression. Our bile 
acid screen demonstrated the effect different bile acids conjugates and amino acids had 
on V. cholerae tcp expression. However, this screen gave an incomplete picture of the 
bile acids seen in the intestinal tract and should be expanded to include conjugated forms 
of LCA, UDCA and other murine forms. For example, we expect that LCA conjugates 
would have lower induction as it is considered more toxic and am interested about the 
effect UDCA has as it is a non-toxic bile acid (32, 36). 
 Taken together, my results suggest that B. obeum ATCC 29174 are antagonistic to 
V. cholerae infections, both by production of quorum sensing molecules but also through 
activity of its bsh enzyme, providing new insight on how colonization of V. cholerae is 
affected by the gut microbiome (84). It is important to note that this antagonistic activity 
may not be not refer to the species as a whole as differences are seen in BSH amino acid 
sequence and function within species (see Figure 8) (51). Many individuals in cholera 
endemic areas exhibit a disrupted microbiome due to malnutrition and non-cholera 
infectious diarrhea. My results suggest that this may in turn feed back into infection 
susceptibility by laying the framework for a V. cholerae infection due to an increase in 
conjugated primary bile acids (97). Based on reports in the literature, and our results, 
establishing and maintaining a resistant microbiome with bacteria containing bsh genes 
from the different phylotypes could decrease the risk of infection; one way to accomplish 
this is through the development of probiotics made up of cultures that have bsh genes and 
species that participate in dehydroxylation. By establishing these microbiomes, the bile 
acid pool can be manipulated in that secondary bile acids are created by the microbiome 
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and increasing the diversity of conjugated bile acid pool, bile acids that do not positively 
affect virulence expression in V. cholerae. There are other ways of manipulating bile acid 
composition, such a high fat diet and cholestyramine; these avenues would not be feasible 
as the acquisition of foods high in fat is more difficult in these developing areas and 
cholestyramine maybe more detrimental by affecting malnourished individuals ability to 
absorb and retain fat needed for survival. These results not only affect the microbial field, 
but also highlights the need for dietary and medical intervention in order to reduce the 
incidences of infection and maintaining a resistant microbiome in individuals.  
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